Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher versus standard adalimumab dosing in moderately to severely active ulcerative colitis
NL-OMON47464Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adalimumab in autoimmune colitis (5 arms), sponsored by AbbVie Inc. Started Jan 2015; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47464.